US2013005953A1PendingUtilityA1

Readthrough Inducing Agent and Drug for Treating Genetic Disease Caused by Nonsense Mutation

Assignee: MATSUDA RYOICHIPriority: Feb 3, 2010Filed: Aug 1, 2012Published: Jan 3, 2013
Est. expiryFeb 3, 2030(~3.5 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 7/04A61P 3/06A61P 37/06A61P 7/00A61P 3/10A61P 5/14A61P 9/02A61P 37/02A61P 9/10A61P 43/00A61P 29/00A61P 3/04A61P 25/00A61P 25/16A61P 25/28A61P 27/02A61P 19/02A61P 21/04A61P 1/16A61P 21/00A61P 17/00A61P 13/12A61P 11/00A61P 19/00A61K 31/7036A61K 48/00C07H 15/234
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.

Claims

exact text as granted — not AI-modified
1 . A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising:
 a compound having a structure expressed by the following Structural Formula (A):   
       
         
           
           
               
               
           
         
       
     
     
         2 . A drug for treating a genetic disease caused by nonsense mutations, the drug comprising:
 a readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations,   wherein the readthrough inducing agent comprises:   a compound having a structure expressed by the following Structural Formula (A):   
       
         
           
           
               
               
           
         
       
     
     
         3 . The drug according to  claim 2 , wherein the genetic disease caused by nonsense mutations is muscular dystrophy.

Join the waitlist — get patent alerts

Track US2013005953A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.